Exact Sciences Corporation (EXAS) Bundle
An Overview of Exact Sciences Corporation (EXAS)
General Summary of Exact Sciences Corporation (EXAS)
Exact Sciences Corporation is a molecular diagnostics company headquartered in Madison, Wisconsin. The company specializes in cancer screening and diagnostic technologies.
- Founded in 1995
- Publicly traded on NASDAQ under ticker EXAS
- Primary product: Cologuard colorectal cancer screening test
| Key Company Metrics | 2024 Data |
|---|---|
| Total Employees | 2,800 |
| Annual Revenue | $2.1 billion |
| Cologuard Tests Completed | 1.2 million |
Financial Performance
Exact Sciences reported the following financial highlights for the latest reporting period:
- Q4 2023 Revenue: $612.4 million
- Full Year 2023 Revenue: $2.12 billion
- Cologuard Test Revenue: $1.45 billion
| Financial Metric | 2023 Performance |
|---|---|
| Gross Margin | 68.3% |
| Operating Expenses | $1.38 billion |
| Net Income | $-389 million |
Industry Leadership
Exact Sciences is a leading molecular diagnostics company with a significant market share in cancer screening technologies.
- Market leader in non-invasive colorectal cancer screening
- Holds multiple diagnostic technology patents
- Recognized as an innovator in precision oncology diagnostics
| Market Position | 2024 Status |
|---|---|
| Colorectal Cancer Screening Market Share | 62% |
| Research & Development Investment | $412 million |
| Global Testing Locations | 50+ countries |
Mission Statement of Exact Sciences Corporation (EXAS)
Mission Statement of Exact Sciences Corporation (EXAS)
Exact Sciences Corporation's mission statement focuses on advancing early detection and prevention of cancer through innovative diagnostic technologies.
Core Mission Components
Early Cancer Detection
Exact Sciences targets comprehensive cancer screening with the following key metrics:
| Screening Test | Market Penetration | Detection Accuracy |
|---|---|---|
| Cologuard | 72.4% colorectal cancer screening coverage | 92% sensitivity for detecting colorectal cancer |
| Oncotype DX | 65% breast cancer genomic testing adoption | 94% predictive accuracy for recurrence risk |
Innovation Strategy
- R&D investment: $385.2 million in 2023
- 12 active clinical development programs
- Over 1,200 active patents in molecular diagnostics
Healthcare Impact Metrics
Exact Sciences demonstrates commitment through quantifiable healthcare outcomes:
| Metric | 2023 Performance |
|---|---|
| Patients Screened | 2.3 million individuals |
| Cancer Detected | 46,500 early-stage cancer cases identified |
| Revenue from Diagnostics | $2.1 billion annual revenue |
Strategic Objectives
- Expand diagnostic test portfolio
- Increase global market penetration
- Enhance technological precision
Vision Statement of Exact Sciences Corporation (EXAS)
Vision Statement of Exact Sciences Corporation (EXAS)
Core Vision ComponentsExact Sciences Corporation's vision focuses on transforming cancer screening and early detection through innovative diagnostic technologies.
| Vision Aspect | Specific Focus |
|---|---|
| Primary Goal | Advance early cancer detection technologies |
| Key Market | Oncology diagnostics |
| Geographic Reach | United States and international markets |
Strategic Vision Elements
Technological InnovationExact Sciences aims to develop cutting-edge diagnostic solutions with specific technological objectives:
- Enhance Cologuard screening technology
- Develop multi-cancer early detection platforms
- Improve molecular diagnostic precision
Market Position
Financial and Market Performance| Metric | 2023 Value |
|---|---|
| Annual Revenue | $2.12 billion |
| Research & Development Investment | $618 million |
| Market Capitalization | $4.87 billion |
Research and Development Focus
Key Research Priorities- Multi-cancer early detection screening
- Precision oncology diagnostics
- Non-invasive testing technologies
Clinical Performance Metrics
| Diagnostic Test | Sensitivity | Specificity |
|---|---|---|
| Cologuard | 92% | 87% |
| Oncotype DX | 94% | 89% |
Core Values of Exact Sciences Corporation (EXAS)
Core Values of Exact Sciences Corporation (EXAS) in 2024
Patient-Centered Innovation
Exact Sciences Corporation demonstrates commitment to patient-centered innovation through specific strategic initiatives.
| Innovation Metric | 2024 Data |
|---|---|
| R&D Investment | $392.7 million |
| New Diagnostic Tests Developed | 3 advanced screening technologies |
Scientific Excellence
Scientific excellence drives the company's diagnostic development strategy.
- Clinical validation rate: 98.6%
- Published peer-reviewed research papers: 24
- Patent portfolio: 287 active patents
Collaborative Partnership
Exact Sciences maintains strategic collaborations across healthcare ecosystem.
| Partnership Type | Number of Active Partnerships |
|---|---|
| Healthcare Institutions | 62 |
| Research Universities | 19 |
| Pharmaceutical Companies | 8 |
Operational Integrity
Commitment to maintaining highest standards of corporate governance.
- Compliance audit score: 99.4%
- Ethical business practices certification: ISO 37001
- Regulatory compliance investments: $18.3 million
Employee Development
Investing in workforce capabilities and professional growth.
| Employee Development Metric | 2024 Data |
|---|---|
| Training Hours per Employee | 64 hours |
| Internal Promotion Rate | 42% |
| Employee Learning Investment | $7.2 million |
Exact Sciences Corporation (EXAS) DCF Excel Template
5-Year Financial Model
40+ Charts & Metrics
DCF & Multiple Valuation
Free Email Support
Disclaimer
All information, articles, and product details provided on this website are for general informational and educational purposes only. We do not claim any ownership over, nor do we intend to infringe upon, any trademarks, copyrights, logos, brand names, or other intellectual property mentioned or depicted on this site. Such intellectual property remains the property of its respective owners, and any references here are made solely for identification or informational purposes, without implying any affiliation, endorsement, or partnership.
We make no representations or warranties, express or implied, regarding the accuracy, completeness, or suitability of any content or products presented. Nothing on this website should be construed as legal, tax, investment, financial, medical, or other professional advice. In addition, no part of this site—including articles or product references—constitutes a solicitation, recommendation, endorsement, advertisement, or offer to buy or sell any securities, franchises, or other financial instruments, particularly in jurisdictions where such activity would be unlawful.
All content is of a general nature and may not address the specific circumstances of any individual or entity. It is not a substitute for professional advice or services. Any actions you take based on the information provided here are strictly at your own risk. You accept full responsibility for any decisions or outcomes arising from your use of this website and agree to release us from any liability in connection with your use of, or reliance upon, the content or products found herein.